Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2011-11-05 Regulatory Filings
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a press release dated November 5, 2011, announcing the presentation of positive Phase III clinical trial data for an investigational Ragweed Allergy Immunotherapy Tablet (AIT) by ALK's partner, Merck, at an allergy conference (ACAAI). It details efficacy results, safety profiles, and the scope of the studies. This type of announcement, focusing on clinical trial results and partnership updates, is typically classified as an Investor Presentation (IP) if it were a deck, or often falls under general Investor Relations communication. Since it is a press release detailing scientific/clinical progress and does not fit the strict definitions of 10-K, ER, IR, or MDA, it is best categorized as an Investor Presentation (IP) as it is material information intended for investors regarding product development, or potentially Regulatory Filings (RNS) if it were purely a regulatory update. Given the detailed clinical data presentation aimed at informing investors about product pipeline progress, 'Investor Presentation' (IP) is the most fitting category among the specific options, although it is structured as a press release. It is not a formal report (10-K, IR) nor a simple earnings announcement (ER). It is a detailed update on a key asset.
2011-11-05 English
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a press release dated November 5, 2011, announcing the presentation of positive Phase III clinical trial data for an investigational Ragweed Allergy Immunotherapy Tablet (AIT) by ALK's partner, Merck, at an allergy conference (ACAAI). It details efficacy results, safety profiles, and the scope of the studies. This type of announcement, focusing on clinical trial results and partnership updates, is typically classified as an Investor Presentation (IP) if it were a deck, or often falls under general Investor Relations communication. Since it is a press release detailing scientific/clinical progress and does not fit the strict definitions of 10-K, ER, IR, or MDA, it is best categorized as an Investor Presentation (IP) as it is material information intended for investors regarding product development, or potentially Regulatory Filings (RNS) if it were purely a regulatory update. Given the detailed clinical data presentation aimed at informing investors about product pipeline progress, 'Investor Presentation' (IP) is the most fitting category among the specific options, although it is structured as a press release. It is not a formal report (10-K, IR) nor a simple earnings announcement (ER). It is a detailed update on a key asset.
2011-11-05 English
Earnings Release 2011
Earnings Release Classification · 99% confidence The document is a 'Selskabsmeddelelse' (Company Announcement) from ALK-Abelló A/S, dated November 5, 2011. It announces that their North American partner, Merck, will present clinical trial data for a ragweed vaccine at the American College of Allergy, Asthma & Immunology (ACAAI) annual meeting. This is an update on clinical development progress and partnership activities, not a full financial report (like 10-K or IR), a formal earnings release (ER), or a dividend notice (DIV). It is a specific announcement regarding ongoing business/development activities, which fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate update, or potentially a general 'Investor Presentation' (IP) if it were the presentation itself, but since it's an announcement *about* data presentation, RNS is the most appropriate fallback for non-standard corporate news. Given the content is a press release style update on clinical trial results and partnership milestones, RNS is the best fit among the provided options, as it is not a specific financial or governance filing type listed. FY 2011
2011-11-05 English
Report Publication Announcement 2011
Report Publication Announcement Classification · 98% confidence The document is very short (1135 characters) and explicitly announces the future release date and time of the 'interim report for the nine months ended 30 September 2011' (which would typically be classified as IR). It also announces a subsequent conference call and where the related presentation will be available. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement regarding the publication of a report, rather than the report itself, should be classified as a Report Publication Announcement (RPA).
2011-11-03 English
Report Publication Announcement 2011
Report Publication Announcement Classification · 98% confidence The document is a short announcement (1053 characters) dated November 3, 2011, stating that ALK will publish its interim report (delårsrapport) for the first 9 months (Q3) 2011 on November 14, 2011. It also announces a conference call for analysts and investors immediately following the release, mentioning where the accompanying presentation will be available. According to Rule #2 (The 'MENU VS MEAL' Rule), a short document announcing the publication of a report, rather than being the report itself, should be classified as a Report Publication Announcement (RPA).
2011-11-03 Danish
Regulatory Filings 2011
Regulatory Filings
2011-09-26 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.